(Q34984075)

5 August 2017

1 reference

title

Introduction to therapy of hepatitis C. (English)

1 reference

5 August 2017

Karen L Lindsay

1

1 reference

PubMed ID

12407584

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

36

1 reference

5 August 2017

5 Suppl 1

1 reference

5 August 2017

S114-20

1 reference

Standardization of hepatitis C virus RNA quantification

5 August 2017

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Long-term follow-up study of sustained biochemical responders with interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Complementary and alternative medicine in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Interferons in host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36226

21 January 2018

Identifiers

DOI

10.1053/JHEP.2002.36226

1 reference

5 August 2017

1 reference

PubMed ID

12407584